Deep Track Capital, LP and affiliated entities filed an amended Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of common stock in Obsidian Therapeutics, Inc. as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: Deep Track Capital, LP and David Kroin each reported beneficial ownership of 2,120,050 shares of Obsidian Therapeutics common stock, representing 3.43% of the class.
- Master fund position: Deep Track Biotechnology Master Fund, Ltd. reported beneficial ownership of 1,935,041 shares, representing 3.13% of the class.
- Special opportunities fund: Deep Track Special Opportunities Fund, LP reported beneficial ownership of 185,009 shares, representing 0.30% of the class.
- Voting and dispositive power: All reporting persons hold zero sole voting or dispositive power; all shares are held with shared voting and shared dispositive power.
- Share count basis: Percentage calculations are based on 61,727,211 shares of common stock outstanding as of August 10, 2026, according to the filing.
- Event date: The filing event triggering this amended statement is dated September 30, 2026.
Deep Track Capital's Amended Ownership Position in Obsidian Therapeutics
According to the amended Schedule 13G filed November 16, 2026, four reporting persons affiliated with the Deep Track Capital group disclosed their combined holdings in Obsidian Therapeutics, Inc. (CUSIP 67448A106), a Cambridge, Massachusetts-based biotechnology company with principal offices at 1030 Massachusetts Avenue. The filing covers common stock with a par value of $0.0001 per share. Deep Track Capital, LP is organized in Delaware and identified as an investment adviser, while Deep Track Biotechnology Master Fund, Ltd. is organized in the Cayman Islands. David Kroin, a United States citizen, is identified as a control person of Deep Track Capital, LP and signed the filing in his capacity as Managing Member of the General Partner of the Investment Adviser.
The filing states that Deep Track Capital, LP and David Kroin each beneficially own 2,120,050 shares, all held with shared voting and shared dispositive power and none with sole authority. Deep Track Biotechnology Master Fund, Ltd. accounts for 1,935,041 of those shares, while Deep Track Special Opportunities Fund, LP holds the remaining 185,009 shares, representing 0.30% of the class. The filing certifies, per Item 5, that each reporting person's ownership represents five percent or less of the class. The share percentages are calculated using 61,727,211 shares outstanding as of August 10, 2026, as reported in the issuer's quarterly report filed with the SEC on August 14, 2026, according to the filing's exhibit information.
The filing's Item 10 certification states that "the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities." The four reporting persons filed jointly pursuant to Rule 13d-1(k), with each party taking responsibility for the accuracy of its own disclosures.
What Was Disclosed
Four Deep Track Capital affiliates filed an amended Schedule 13G disclosing aggregate beneficial ownership of 2,120,050 shares of Obsidian Therapeutics common stock, equal to 3.43% of the class, as of September 30, 2026, with all voting and dispositive power held on a shared basis.



Please wait processing your request...